1h Free Analyst Time
The bispecific antibodies for cancer market is forecasted to grow by USD 314.3 million during 2023-2028, accelerating at a CAGR of 6.78% during the forecast period. The report on the bispecific antibodies for cancer market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of cancer, advantages of bispecific antibodies over monoclonal antibodies, and strong pipeline.
The bispecific antibodies for cancer market is segmented as below:
By Type
- CD19 or CD3
- CD30 or CD16A
By Distribution Channel
- Hospitals
- Retail pharmacies
- Online
By Geography
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the bispecific antibodies for cancer market covers the following areas:
- Bispecific antibodies for cancer market sizing
- Bispecific antibodies for cancer market forecast
- Bispecific antibodies for cancer market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global bispecific antibodies for Cancer market: ABL Bio Inc., AFFIMED N.V., Akeso Inc., Amgen Inc., Aptevo Therapeutics Inc., Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd., Eli Lilly and Co., EPIMAB BIOTHERAPEUTICS INC., F STAR THERAPEUTICS INC., F. Hoffmann La Roche Ltd., Glenmark Pharmaceuticals Ltd., Johnson and Johnson Services Inc., Mereo BioPharma Group PLC, Merus N.V., Pfizer Inc., Regeneron Pharmaceuticals Inc., TG Therapeutics Inc., Vadilal Industries Ltd., and Y mAbs Therapeutics Inc..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is emerging bispecific antibody generation platforms."
According to the report, one of the major drivers for this market is the increasing prevalence of Cancer.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- ABL Bio Inc.
- AFFIMED N.V.
- Akeso Inc.
- Amgen Inc.
- Aptevo Therapeutics Inc.
- Astellas Pharma Inc.
- Chugai Pharmaceutical Co. Ltd.
- Eli Lilly and Co.
- EPIMAB BIOTHERAPEUTICS INC.
- F STAR THERAPEUTICS INC.
- F. Hoffmann La Roche Ltd.
- Glenmark Pharmaceuticals Ltd.
- Johnson and Johnson Services Inc.
- Mereo BioPharma Group Plc
- Merus N.V.
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- TG Therapeutics Inc.
- Vadilal Industries Ltd.
- Y mAbs Therapeutics Inc.
